Cantor Fitzgerald Downgrades Centene (CNC) to Hold; Shortfall Is A Big Psychological Blow To Medicaid Names
Tweet Send to a FriendGet Alerts CNC Hot Sheet
Price: $50.06 -2.49%
Rating Summary:
5 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade CNC Now!
Cantor Fitzgerald downgraded Centene (NYSE: CNC) from Buy to Hold with a price target of $29.00 (from $46.00).
Analyst, Joseph D. France, said, "Centene's announcement this morning of major cost problems in Kentucky and Texas (new markets), and problems with the individual business in Massachusetts, marks its first significant earnings disappointment in years, and we expect it to weigh on the group for a while. Adverse selection, retroactive assignments and delays in filing claims are common enough problems in the industry, but as a leading pure play Medicaid name, Centene's experience raises concern about new markets to come, and the role of these companies as a group in the handling of more complex disabled and dual eligible cases."
"...lowered our EPS estimates from $2.75 to $1.50 in 2012 and from $3.15 to $2.00 in 2013."
For an analyst ratings summary and ratings history on Centene click here. For more ratings news on Centene click here.
Shares of Centene closed at $35.47 yesterday, with a 52 week range of $25.28-$50.98.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Joseph D. France, said, "Centene's announcement this morning of major cost problems in Kentucky and Texas (new markets), and problems with the individual business in Massachusetts, marks its first significant earnings disappointment in years, and we expect it to weigh on the group for a while. Adverse selection, retroactive assignments and delays in filing claims are common enough problems in the industry, but as a leading pure play Medicaid name, Centene's experience raises concern about new markets to come, and the role of these companies as a group in the handling of more complex disabled and dual eligible cases."
"...lowered our EPS estimates from $2.75 to $1.50 in 2012 and from $3.15 to $2.00 in 2013."
For an analyst ratings summary and ratings history on Centene click here. For more ratings news on Centene click here.
Shares of Centene closed at $35.47 yesterday, with a 52 week range of $25.28-$50.98.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, DowngradesRelated Entities
Cantor Fitzgerald, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
